The article discusses the potential of myocardial remuscularization through cardiomyocyte implantation, indicating strong evidence from large animal studies. It highlights the limitations of small animal studies, particularly xenograft models, due to immune responses impacting long-term effectiveness. The authors emphasize that therapeutic effects observed in these models may be influenced by immune mechanisms rather than true remuscularization. They point out the advantages of allograft studies with effective immunosuppression, which demonstrated that grafts containing cardiomyocytes are superior to non-myocyte grafts, thus supporting the hypothesis of functional remuscularization.
Myocardial remuscularization through cardiomyocyte implantation shows promise in large animal studies, suggesting functional remuscularization can effectively address heart failure.
Although small animal studies are essential for early proof of concept, their predictive reliability for human heart failure outcomes remains questionable due to immune responses.
Our data indicate that immune responses and paracrine mechanisms might mediate the therapeutic effects observed in xenograft models, emphasizing the complexity of cardiac repair.
Effective immunosuppression in allograft studies demonstrates that cardiomyocyte-containing engineered heart muscle outperforms non-myocyte grafts, highlighting myocyte-specific functional benefits.
#myocardial-remuscularization #cardiomyocyte-implantation #heart-failure #xenograft-studies #allograft-efficacy
Collection
[
|
...
]